Promacta® (eltrombopag) – New warning
October 4, 2017 – The FDA approved an update to the Warnings and Precautions section of the Promacta (eltrombopag) drug label regarding the increased risk of death and progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML).
Download PDF
